^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo’s DS-1062 in Patients with Advanced NSCLC at 2019 World Conference on Lung Cancer

Published date:
07/10/2020
Excerpt:
Thirty-five patients were evaluable for TROP2 expression by immunohistochemistry (IHC) analysis. TROP2 expression trended higher in patients who experienced a partial response.